Abstract: The asialoglycoprotein receptor(ASGPR) localizes on the parenchymal liver cells, by coupling with the special ligands radiolabeled tumor necrosis factor, it can selectively direct to the liver cells. It is promising hepatic targeting radiolabeled tumor necrosis factor which can act locally on hepatic carcinoma, improve the ratio of liver to nonliver, and reduce the side effect in order to developing the anticarcinoma action of TNF and increasing the apoptosis of hepatic carcinoma. The study aim is to reduce or prevent the recurrence of postoperated liver cancer and improve the remission to develop the biefficacy drugs both radioactivity and biological therapy on hepatic targeting